Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Immunol ; 176: 63-70, 2017 03.
Article in English | MEDLINE | ID: mdl-28025135

ABSTRACT

Cancer is currently treated by a combination of therapies, including chemotherapy which is believed to suppress the immune system. Combination of immunotherapy and chemotherapy correlates with improved survival but needs careful planning in order to achieve a synergistic effect. In this study, we have demonstrated that doxorubicin treatment of B cells resulted in increased expression of CD86 and concordantly increased CD4+ T cell activation in the presence of superantigen, an effect that was inhibited by the addition of a CD86 blocking antibody. Furthermore, doxorubicin resulted in decreased expression of the anti-inflammatory cytokines IL-10 and TNF-α. Finally, B cells from urinary bladder cancer patients, treated with a neoadjuvant regiment containing doxorubicin, displayed increased CD86-expression. We conclude that doxorubicin induces CD86 expression on B cells and hence enhances their antigen-presenting ability in vitro, a finding verified in patients. Development of tailored time and dose schedules may increase the effectiveness of combining chemotherapy and immunotherapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/immunology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , B-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/drug effects , Lymphocyte Activation/drug effects , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/therapy , Aged , Aged, 80 and over , Antigen Presentation/drug effects , Antigen Presentation/immunology , Antigen-Presenting Cells/drug effects , Antigen-Presenting Cells/immunology , B-Lymphocytes/immunology , B7-2 Antigen/immunology , CD4-Positive T-Lymphocytes/immunology , Doxorubicin/administration & dosage , Female , Humans , Immunotherapy/methods , Interleukin-10/immunology , Lymphocyte Activation/immunology , Male , Middle Aged , Tumor Necrosis Factor-alpha/immunology , Urinary Bladder Neoplasms/immunology
2.
Br J Cancer ; 115(8): 957-966, 2016 10 11.
Article in English | MEDLINE | ID: mdl-27599044

ABSTRACT

BACKGROUND: Stage is an important prognostic factor in renal tumours and dissemination to regional lymph nodes is associated with poor outcomes. Lymph nodes are routinely assessed by immunohistochemistry and microscopic evaluation, a time-consuming process where micrometastases might go undiagnosed. We evaluate an alternative method for detecting metastatic cells in sentinel nodes (SNs) by flow cytometry. METHODS: A total of 15 nodes from 5 patients diagnosed with renal tumours were analysed by flow cytometry. Staining for the intracellular marker cytokeratin 18 (CK18) with the surface markers carbonic anhydrase IX (CA9) and Cadherin 6 were used in flow cytometry analysis. Peripheral blood mononuclear cells (PBMCs) with the addition of known concentrations of cancer cell lines were analysed to investigate the sensitivity of micrometastasis detection. RESULTS: Stability of the assay was marked by low intra-assay variability (coefficient of variance ⩽16%) and low inter-assay variability (R2=0.9996-1). Eight nodes in four patients were positive for metastasis; six of them were considered being micrometastatic. These metastases were undetected by routine pathology and the patients were restaged from pN0 to pN1. CONCLUSIONS: Flow cytometry is able to detect micrometastases in lymph nodes of renal tumour patients that were undetected under H&E examination.


Subject(s)
Carcinoma, Renal Cell/secondary , Flow Cytometry/methods , Kidney Neoplasms/pathology , Sentinel Lymph Node Biopsy/methods , Sentinel Lymph Node/pathology , Adenoma, Oxyphilic/chemistry , Adenoma, Oxyphilic/diagnosis , Adenoma, Oxyphilic/pathology , Adenoma, Oxyphilic/secondary , Aged , Antigens, Neoplasm/analysis , Biomarkers, Tumor , Cadherins/analysis , Carbonic Anhydrase IX/analysis , Carcinoma, Renal Cell/chemistry , Carcinoma, Renal Cell/diagnosis , Carcinoma, Renal Cell/pathology , Cell Line, Tumor , Eosine Yellowish-(YS) , False Negative Reactions , Female , Hematoxylin , Humans , Keratin-18/analysis , Kidney Neoplasms/chemistry , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Micrometastasis/diagnosis , Neoplasm Proteins/analysis , Sensitivity and Specificity , Staining and Labeling
3.
PLoS One ; 7(5): e36422, 2012.
Article in English | MEDLINE | ID: mdl-22567156

ABSTRACT

BACKGROUND: Hypoxic ischemia (HI) is an important cause of neonatal brain injury and subsequent inflammation affects neurological outcome. In this study we performed investigations of systemic and local activation states of inflammatory cells from innate and adaptive immunity at different time points after neonatal HI brain injury in mice. METHODOLOGY/PRINCIPAL FINDINGS: We developed a multiplex flow cytometry based method combined with immunohistochemistry to investigate cellular immune responses in the brain 24 h to 7 months after HI brain injury. In addition, functional studies of ex vivo splenocytes after cerebral hypoxic ischemia were performed. Both central and peripheral activation of CD11b(+) and CD11c(+) antigen presenting cells were seen with expression of the costimulatory molecule CD86 and MHC-II, indicating active antigen presentation in the damaged hemisphere and in the spleen. After one week, naïve CD45rb(+) T-lymphocytes were demonstrated in the damaged brain hemisphere. In a second phase after three months, pronounced activation of CD45rb(-) T-lymphocytes expressing CD69 and CD25 was seen in the damaged hemisphere. Brain homogenate induced proliferation in splenocytes after HI but not in controls. CONCLUSIONS/SIGNIFICANCE: Our findings demonstrate activation of both local and systemic immune responses months after hypoxic ischemic neonatal brain injury. The long term immune activation observed is of general importance for future studies of the inflammatory response after brain injury as most previous studies have focused on the first few weeks after damage, while the effects of the late inflammation phase may be missed. Furthermore, the self-reactive component raises the question if there is a correlation with development of autoimmune brain disease later in life.


Subject(s)
Brain Ischemia/immunology , Hypoxia-Ischemia, Brain/immunology , Inflammation/immunology , Animals , Animals, Newborn , Flow Cytometry , Immunohistochemistry , Mice
SELECTION OF CITATIONS
SEARCH DETAIL
...